Table 1.
Baseline characteristics of the study population.
| Coagulative necrosis | Liquefactive necrosis | P value | |
|---|---|---|---|
| No. of patients | 79 (46.2%) | 92 (53.8%) | |
| Gender | |||
| Men | 73 (92.4%) | 79 (85.9%) | 0.225 |
| Women | 6 (7.6%) | 13 (14.1%) | |
| Age | |||
| >60 years | 32 (40.5%) | 27 (29.3%) | 0.148 |
| <60 years | 47 (59.5%) | 65 (70.7%) | |
| Alpha-fetoprotein | |||
| >400 ng/ml | 47 (59.5%) | 50 (54.3%) | 0.538 |
| <400 ng/ml | 32 (40.5%) | 42 (45.7%) | |
| HBV or HCV | 69 (87.3%) | 75 (81.5%) | 0.401 |
| Liver cirrhosis | 38 (48.1%) | 45 (48.9%) | 1.00 |
| Child-Pugh | 5.76±0.91 | 5.72±0.94 | 0.767 |
| Class B (7–9) | 13 (16.5%) | 17 (18.5%) | 0.841 |
| Class A (5–6) | 66 (83.5%) | 75 (81.5%) | |
| Total bilirubin (umol/L) | 22.63±24.08 | 23.06±27.73 | 0.913 |
| Albumin (g/L) | 36.71±4.63 | 36.13±4.02 | 0.382 |
| Prothrombin time (s) | 11.62±1.37 | 11.42±1.31 | 0.342 |
| Ascites | 0.13±0.34 | 0.10±0.30 | 0.554 |
| Hepatic encephalopathy | 0 | 0 | - |
| Barcelona Clinic Liver Cancer | |||
| Stage B | 18 (22.8%) | 11 (12.0%) | 0.068 |
| Stage C | 61 (77.2%) | 81 (88.0%) | |
| Extrahepatic metastasis | 14 (17.7%) | 26 (28.3%) | 0.147 |
| Intrahepatic vessel invasion | 53 (67.1%) | 73 (79.3%) | 0.082 |
| TACE frequency | 8.68±3.97 | 5.63±3.59 | 0.000 |
| Other treatments | |||
| Systemic therapy | 8 (10.1%) | 13 (14.1%) | 0.513 |
| Local therapy | 9 (11.4%) | 8 (8.7%) | |
| Survival status | |||
| Dead | 70 (88.6%) | 79 (85.9%) | 0.652 |
| Censored | 9 (11.4%) | 13 (14.1%) | |
HBV – hepatitis B virus; HCV – hepatitis C virus; TACE – transarterial chemoembolization. P<0.05 was considered a statistically significant difference.